
T-3256336
CAS No. 1266227-69-3
T-3256336( T3256336 | T 3256336 )
Catalog No. M11118 CAS No. 1266227-69-3
A potent, selective, orally available IAP antagonist with IC50 of 1.3, 2.2 and 200 nM for cIAP-1, cIAP-2 and XIAP, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 963 | Get Quote |
![]() ![]() |
50MG | 1962 | Get Quote |
![]() ![]() |
100MG | 2520 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameT-3256336
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, orally available IAP antagonist with IC50 of 1.3, 2.2 and 200 nM for cIAP-1, cIAP-2 and XIAP, respectively.
-
DescriptionA potent, selective, orally available IAP antagonist with IC50 of 1.3, 2.2 and 200 nM for cIAP-1, cIAP-2 and XIAP, respectively; dose dependently antagonizes XIAP and promotes the activities of caspase-3 with EC50 of 1.3 uM in cell-free assays, induces the rapid proteasomal degradation of cIAP-1 and activates TNF-α-dependent extrinsic apoptosis signaling in cultured cells; induces cIAP-1 degradation, TNF-α production and caspase activation in cancer xenograft models.
-
In Vitro——
-
In VivoAnimal Model:Female BALB/cAJcl mice (MDA-MB-231-Luc xenograft)Dosage:30, 100 mg/kg Administration:P.o.Result:Stimulated caspase-3/7 activity in a dose-dependent manner, induced tumor regression in a dose-dependent manner with a percent tumor growth inhibition (T/C) of 53% and 62% at 30 mg/kg and 100 mg/kg, respectively.
-
SynonymsT3256336 | T 3256336
-
PathwayApoptosis
-
TargetIAP
-
RecptorIAP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1266227-69-3
-
Formula Weight605.728
-
Molecular FormulaC31H45F2N5O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C([C@H]1N(C([C@H](C2CCC(F)(F)CC2)NC([C@H](C)NC)=O)=O)C[C@](C[C@@H](OCC)C3)([H])N3C1)N[C@@H]4CCOC5=C4C=CC=C5
-
Chemical NamePyrrolo[1,2-a]pyrazine-3-carboxamide, 2-[(2S)-2-(4,4-difluorocyclohexyl)-2-[[(2S)-2-(methylamino)-1-oxopropyl]amino]acetyl]-N-[(4R)-3,4-dihydro-2H-1-benzopyran-4-yl]-7-ethoxyoctahydro-, (3S,7R,8aR)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sumi H, et al. Mol Cancer Ther. 2013 Feb;12(2):230-40.
2. Hashimoto K, et al. J Med Chem. 2013 Feb 14;56(3):1228-46.
3. Sumi H, et al. Biochem Biophys Res Commun. 2016 Oct 14;479(2):179-185.
molnova catalog



related products
-
SM-164
SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains (IC50: 1.39 nM). It acts as an extremely potent antagonist of XIAP. SM-164 binds to XIAP being 300 and 7000-times more potent than its monovalent counterparts and the natural Smac AVPI peptide, respectively.
-
MX107
MX107 is a novel potent survivin inhibitor, effectively suppresses MDA-MB-231 cells proliferation with IC50 of 3.1 uM.
-
HM90822
HM90822 is a novel synthetic apoptotic protein (IAP) antagonist that induces apoptosis in human pancreatic cancer cells through proteasome-dependent degradation of IAPs containing the BIR2/3 structural domain.